Xencor, Inc. XNCR
Xencor, Inc. (Nasdaq: XNCR) is an oncology drug developer. Its lead program, XmAb819, is in Phase 3 for clear cell renal cell carcinoma (ccRCC). Its next catalyst on record is XmAb819: Planned Phase 3 pivotal study for advanced ccRCC (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: XmAb819 — Planned Phase 3 pivotal study for advanced ccRCC (H2 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| XmAb819 | clear cell renal cell carcinoma (ccRCC) | antibody | Phase 3 |
| XmAb942 | ulcerative colitis (UC) | antibody | Phase 2 |
| XmAb541 | high-grade serous ovarian carcinoma and germ cell tumors | antibody | Phase 2 |
| XmAb541 + XmAb808 | CLDN6-expressing tumors (ovarian cancer) | antibody | Phase 1 |
| Plamotamab | rheumatoid arthritis (RA) | antibody | Phase 1 |
| XmAb657 | idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), Sjögren's disease | antibody | Phase 1 |
| XmAb412 | autoimmune and inflammatory disease | antibody | Phase 1 |
| XmAb808 | B7-H3-expressing tumors (combination with XmAb541) | antibody | Phase 1 |
Recent results and decisions
- started XmAb412 first-in-human study open for enrollment in healthy participants.
XmAb412 (TL1A x IL23p19) first-in-human healthy participant study open for enrollment.
Filing - started Xencor initiated first-in-human study of XmAb412 in Q3 2026.
Xencor initiated a first-in-human study of XmAb412 in the third quarter of 2026.
Filing - started A sub-study for patients with ENPP3+ advanced colorectal cancer, NSCLC and papillary RCC began enrollment in Q2 2026.
A sub-study for patients with ENPP3+ advanced colorectal cancer, non-small cell lung cancer and papillary renal cell carcinoma began enrollment in the second quarter of 2026.
Filing
7 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.